Evidence map›Paper›PMID 24371771›Full record

ArticleLeukemia research reports2013

Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML).

Victor Chow, Kathleen Shannon Dorcy, Ravinder Sandhu, Kelda Gardner, Pamela Becker, John Pagel, Paul Hendrie, Janis Abkowitz, Frederick Appelbaum, Elihu Estey

Open access · goldAbstract read
In one paragraph

Article in Leukemia research reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Victor ChowUniversity of Washington School of Medicine, Seattle, USA ; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA.
Kathleen Shannon DorcyFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA.
Ravinder SandhuFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA.
Kelda GardnerFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA ; Seattle Cancer Care Alliance, Seattle, USA.
Pamela BeckerUniversity of Washington School of Medicine, Seattle, USA ; Institute for Stem Cell and Regenerative Medicine, Seattle, USA.
John PagelUniversity of Washington School of Medicine, Seattle, USA ; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA ; Seattle Cancer Care Alliance, Seattle, USA.
Paul HendrieUniversity of Washington School of Medicine, Seattle, USA ; Seattle Cancer Care Alliance, Seattle, USA.
Janis AbkowitzUniversity of Washington School of Medicine, Seattle, USA.
Frederick AppelbaumUniversity of Washington School of Medicine, Seattle, USA ; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA ; Seattle Cancer Care Alliance, Seattle, USA.
Elihu EsteyUniversity of Washington School of Medicine, Seattle, USA ; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA ; Seattle Cancer Care Alliance, Seattle, USA.
Seattle University · USFred Hutch Cancer Center · USSeattle Cancer Care Alliance · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHospital admission for neutropenic fever in patients with AML is a standard practice. However, discharge practices vary once patients become afebrile, with many patients hospitalized until rise in the absolute neutrophil count (ANC) to >500 (ANC recovery). Data to support this practice are sparse. We hypothesized that patients admitted for neutropenic fever, particularly if in complete remission (CR) or about to enter CR following the chemotherapy course associated with neutropenic fever, might be safely discharged earlier (ED). Benefits of ED are less exposure to hospital pathogens, reduced cost, increased availability of beds for patients more in need of urgent care, and potentially, enhanced psychological well-being.

methodsWe identified patients age 18-70 with newly diagnosed AML who were admitted to the University of Washington Medical Center with neutropenic fever between January 2008 and May 2010. We compared subsequent (within 30 days of discharge) deaths, intensive care unit (ICU) admissions, and readmissions for neutropenic fever according to discharge ANC, regarded as a numerical variable using the Mann-Whitney U test and as <500 vs >500 using the Fisher Exact test. We used the Mann-Whitney U or Spearman correlation to analyze the relation between ANC at discharge and other covariates that might have affected outcome: age, ECOG performance status at admission for neutropenic fever, days inpatient, remission status, and type of infection (pneumonia, gram negative bacteremia, others).

resultsWe evaluated 49 patients discharged after admission for neutropenic fever, 26 of whom were discharged with an ANC <500. Thirty five of the patients were in CR or entered CR following the chemotherapy course associated with their neutropenic fever admission. Patients who were discharged with lower ANC were more likely to be readmitted with neutropenic fever (Mann-Whitney U p=0.03), although this was not true using ANC categorized as < vs >500 (Fisher Exact p=0.24, 95% confidence interval -0.47, 0.11). There was no relation between ANC at discharge and subsequent admission to an ICU (Mann-Whitney U p=0.50, Fisher Exact p=0.64, 95% confidence interval 0.2, 0.34 using the 500 ANC cut off). One patient died: a 55 year old discharged with ANC 0 after successful treatment of neutropenic fever died 19 days after hospital readmission with fever of unknown origin. Stenotrophomonas maltophilia pneumonia and sepsis were discovered 14 days after readmission. Assuming a beta distribution and rates of death of 1/26 for discharge with ANC<500 and 0/23 for discharge with ANC>500, the probability that a discharge ANC with <500 is associated with a higher death rate is 0.019. The number of events was too small for a multivariate analysis. However, patients with better performance status (<ECOG 2) or who spent a shorter time in hospital after admission for neutropenic fever were more likely to be discharged with lower ANC (Fisher exact p=0.09 and Spearman p=0.02 respectively), while the likelihood of discharge with ANC<500 was unrelated to age, remission status, or type of infection. Thus we examined the relation between ANC and readmission for neutropenic fever separately in patients with better or worse performance status and in patients who spent more or less than the median time (8 days) in hospital after admission for neutropenic fever. This analysis indicated that patients discharged with lower ANC were more likely to be readmitted only if they had spent more than 8 days in hospital or if they were performance status <2.

conclusionsOur results suggest that an ANC of 500 is an excessively high cut off for discharge following hospitalization for neutropenic fever. The rate of rise of the ANC, as well as its absolute value, may also play a role.

Indexed as

DischargeFeverLeukemiaNeutropenicNeutrophil

Identifiers

PMID24371771
PMCPMC3850377
OpenAlexW2028443625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.